Patents Assigned to Relay Therapeutics, Inc.
-
Patent number: 11890281Abstract: The disclosure is in part directed to crystalline forms of (R)-1?-(3-(3,4-dihydro-1,5-naphthyridin-1(2H)-yl)-1H-pyrazolo[3,4-b]pyrazin-6-yl)-3H-spiro[benzofuran-2,4?-piperidin]-3-amine, its salt, and variants thereof.Type: GrantFiled: September 23, 2020Date of Patent: February 6, 2024Assignee: Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, André Lescarbeau, Jing Wang, Yanyan Zhang, Gaodeng Lian
-
Patent number: 11780845Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of FGFR enzymes with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with FGFR signaling with the compounds and compositions of the disclosure.Type: GrantFiled: January 31, 2023Date of Patent: October 10, 2023Assignees: Relay Therapeutics, Inc., D.E. Shaw Research, LLCInventors: Bakary-Barry Touré, Heike Schoenherr, Fabrizio Giordanetto, Demetri T. Moustakas, Brandi M. Hudson
-
Patent number: 11701354Abstract: Cellular biological activities are tightly controlled by intracellular signaling processes initiated by extracellular signals. Protein tyrosine phosphatases, which remove phosphate groups from tyrosine phosphorylated signaling molecules, play equally important tyrosine roles as protein kinases in signal transduction. SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signal relay from the cell surface to the nucleus, and is a critical intracellular regulator in mediating cell proliferation and differentiation.Type: GrantFiled: September 28, 2018Date of Patent: July 18, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
-
Patent number: 11629145Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds ad compositions of the invention.Type: GrantFiled: October 24, 2017Date of Patent: April 18, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, Lucian V. Dipietro, Elizabeth H. Kelley, André Lescarbeau, Mark Andrew Murcko, Levi Charles Thomas Pierce, Kelley C. Shortsleeves, W. Patrick Walters, Sathesh Bhat, Eric Therrien, Markus Kristofer Dahlgren
-
Patent number: 11591336Abstract: The present disclosure relates to compounds of formula (I) and pharmaceutical compositions thereof and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.Type: GrantFiled: May 25, 2018Date of Patent: February 28, 2023Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, Lucian V. DiPietro, W. Patrick Walters, Mark Andrew Murcko, Levi Charles Thomas Pierce, Yong Tang, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Sathesh Bhat, Markus Kristofer Dahlgren, Eric Therrien
-
Patent number: 11529347Abstract: The present invention relates to novel compounds having the general formula: and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further relates to, but is not limited to, methods for suppressing tumor cell growth, ameliorating the pathogenesis of systemic lupus erythematosus, and the treatment of various other disorders, including Noonan syndrome, diabetes, neutropenia, neuroblastoma, melanoma, juvenile leukemia, juvenile myelomonocytic leukemia, chronic myelomonocytic leukemia, acute myeloid leukemia, and other cancers associated with SHP2 deregulation with the compounds and compositions of the invention, alone or in combination with other treatments.Type: GrantFiled: September 22, 2017Date of Patent: December 20, 2022Assignees: Relay Therapeutics, Inc., D. E. Shaw Research, LLCInventors: Brian K. Albrecht, Fabrizio Giordanetto, Jack Benjamin Greisman, Paul Maragakis, Alexander M. Taylor, W. Patrick Walters
-
Patent number: 11529348Abstract: Cellular biological activities are tightly controlled by intracellular signaling processes initiated by extracellular signals. Protein tyrosine phosphatases, which remove phosphate groups from tyrosine phosphorylated signaling molecules, play equally important tyrosine roles as protein kinases in signal transduction. SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase, is involved in the signaling pathways of a variety of growth factors and cytokines. Recent studies have clearly demonstrated that this phosphatase plays an important role in transducing signal relay from the cell surface to the nucleus, and is a critical intracellular regulator in mediating cell proliferation and differentiation.Type: GrantFiled: September 28, 2018Date of Patent: December 20, 2022Assignees: D. E. Shaw Research, LLC, Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien, Sathesh Bhat, Markus Kristofer Dahlgren
-
Patent number: 10934302Abstract: The present disclosure relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the disclosure. The present disclosure further relates to, but is not limited to, methods for treating disorders associated with SHP2 deregulation with the compounds and compositions of the disclosure.Type: GrantFiled: May 28, 2020Date of Patent: March 2, 2021Assignee: Relay Therapeutics, Inc.Inventors: Alexander M. Taylor, André Lescarbeau, Elizabeth H. Kelley, Kelley C. Shortsleeves, W. Patrick Walters, Mark Andrew Murcko, Fabrizio Giordanetto, Eric Therrien